Signature Estate & Investment Advisors LLC Has $361,000 Stake in Pfizer Inc. (NYSE:PFE)
Signature Estate & Investment Advisors LLC lifted its position in Pfizer Inc. (NYSE:PFE) by 20.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 9,804 shares of the biopharmaceutical company’s stock after acquiring an additional 1,673 shares during the period. Signature Estate & Investment Advisors LLC’s holdings in Pfizer were worth $361,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Morgan Stanley raised its stake in shares of Pfizer by 6.4% in the third quarter. Morgan Stanley now owns 46,069,866 shares of the biopharmaceutical company’s stock valued at $1,690,763,000 after purchasing an additional 2,777,676 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Pfizer by 0.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 39,996,916 shares of the biopharmaceutical company’s stock valued at $1,467,887,000 after purchasing an additional 143,779 shares in the last quarter. Sanders Capital LLC raised its stake in shares of Pfizer by 2.2% in the third quarter. Sanders Capital LLC now owns 28,895,978 shares of the biopharmaceutical company’s stock valued at $1,183,645,000 after purchasing an additional 613,967 shares in the last quarter. California Public Employees Retirement System raised its stake in shares of Pfizer by 2.4% in the third quarter. California Public Employees Retirement System now owns 18,944,275 shares of the biopharmaceutical company’s stock valued at $695,255,000 after purchasing an additional 440,444 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Pfizer by 4.6% in the second quarter. Principal Financial Group Inc. now owns 13,412,027 shares of the biopharmaceutical company’s stock valued at $438,573,000 after purchasing an additional 587,393 shares in the last quarter. Institutional investors and hedge funds own 69.08% of the company’s stock.
In related news, major shareholder Pfizer Inc bought 1,200,000 shares of the business’s stock in a transaction on Tuesday, October 27th. The shares were purchased at an average price of $10.00 per share, with a total value of $12,000,000.00. Following the completion of the purchase, the insider now owns 27,349,211 shares of the company’s stock, valued at approximately $273,492,110. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.08% of the company’s stock.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.01. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The firm had revenue of $12.13 billion for the quarter, compared to analyst estimates of $12.30 billion. During the same quarter in the prior year, the firm posted $0.75 earnings per share. The company’s quarterly revenue was down 4.3% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.84 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 5th. Shareholders of record on Friday, January 29th will be paid a $0.39 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Thursday, January 28th. This represents a $1.56 annualized dividend and a yield of 4.23%. Pfizer’s dividend payout ratio is presently 51.53%.
A number of research analysts recently commented on the company. Sanford C. Bernstein assumed coverage on Pfizer in a research note on Tuesday, November 10th. They issued a “market perform” rating and a $42.00 target price for the company. Barclays upped their price target on Pfizer from $35.00 to $37.00 and gave the company an “equal weight” rating in a research report on Friday, December 4th. JPMorgan Chase & Co. set a $36.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Monday, November 9th. Truist initiated coverage on Pfizer in a research report on Friday, October 23rd. They issued a “buy” rating and a $42.00 price target on the stock. Finally, The Goldman Sachs Group set a $40.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Friday, January 8th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $39.87.
Pfizer Company Profile
Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.
Recommended Story: What is a dead cat bounce?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.